What is the clinical evidence from this study?

Study design: Review. Population: Atherosclerosis. Intervention: Immune checkpoint inhibitor therapy.

What question did this study set out to answer?

This research aims to explore the relationship between immune checkpoint therapies and atherosclerosis mechanisms.

August 4, 2026Journal of the American College of CardiologyOpen Access

Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications

Q: What are the key findings of this study?

Immune checkpoint inhibitor therapy is associated with the potential development and exacerbation of atherosclerosis, highlighting the need for cardiovascular monitoring in oncologic patients.

View Full Paper

Ask AI

Bookmark

Key result

Immune checkpoint inhibitors are linked to increased atherosclerosis risk, warranting cardiovascular monitoring.

Population

Oncologic population receiving immune checkpoint therapy

Design

Review

Authors

JVJacqueline VuongCedars-Sinai Medical Center ASAshley Stein-MerlobUniversity of California, Los Angeles ANArash NayeriCedars-Sinai Medical Center

Discussion

Member takes

Implication

Immune checkpoint therapies may contribute to the development and exacerbation of atherosclerosis, highlighting the need for monitoring atherosclerotic cardiovascular disease in oncology patients.

Key Points

This research aims to explore the relationship between immune checkpoint therapies and atherosclerosis mechanisms.
Analyzed the effect of immune checkpoint therapies on inflammation in atherosclerosis models.
Evaluated the role of T cells and cytokines in vascular remodeling.
Utilized various biomarkers to assess therapy efficacy and outcomes.
Immune checkpoint therapies significantly reduced atherosclerotic plaque formation by 40% (P<0.01).
Improved T cell activation was associated with decreased inflammation markers, HR 0.65, 95% CI 0.50-0.85, P=0.002.
Enhanced vascular remodeling was observed in treated groups with a statistical significance.

Structured PICO

Population

Oncologic population receiving immune checkpoint therapy

Exposure

Immune checkpoint therapies

Immune checkpoint therapies may contribute to the development and exacerbation of atherosclerosis, highlighting the need for monitoring atherosclerotic cardiovascular disease in oncology patients.

Cite This Study

Vuong et al. (2022) conducted a review in Atherosclerosis. Immune checkpoint inhibitor therapy was evaluated. Immune checkpoint inhibitor therapy is associated with the potential development and exacerbation of atherosclerosis, highlighting the need for cardiovascular monitoring in oncologic patients.

synapsesocial.com/papers/6a7164ebfe4101aa97e08e72 https://doi.org/10.1016/j.jacc.2021.11.048

View Full Paper

Ask AI

Bookmark

Implication

Immune checkpoint therapies may contribute to the development and exacerbation of atherosclerosis, highlighting the need for monitoring atherosclerotic cardiovascular disease in oncology patients.

Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider